ReviewBone reports2024
Tumor-induced osteomalacia: A systematic literature review.
Review in Bone reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical characteristics of pediatric tumor-induced osteomalacia: a systematic review and individual patient data analysis.Frontiers in endocrinology · 2026Pooled it
- Tumor-induced osteomalacia caused by fibroblast growth factor 23 excess : Delayed diagnosis resulting from overlooked hypophosphatemia-A case report.Wiener klinische Wochenschrift · 2026Article
- Real-world outcomes in patients with tumor-induced osteomalacia treated vs not treated with burosumab.Journal of the Endocrine Society · 2026Article
- Burden of Disease in Pediatric Tumor-Induced Osteomalacia: A Literature Review.Calcified tissue international · 2026Review
- Phosphaturic Mesenchymal Tumor: From Invisibility to Bedridden Morbidity.Journal of the ASEAN Federation of Endocrine Societies · 2026Article
- Article
- Importance of Recognizing Renal Tubular Disorders as a Cause of Bone Hypomineralization and Fractures in Adults.Diagnostics (Basel, Switzerland) · 2026Review
- A Case of Tumor-Induced Osteomalacia Masked by Parathyroid Carcinoma.Journal of clinical medicine · 2026Article
- Article
- Global perspectives on the burden and management of hypophosphataemic osteomalacia in adult patients: an International Osteoporosis Foundation (IOF) survey.Archives of osteoporosis · 2026Article
- Preoperative Burosumab With Delayed FGF23 Recovery and High Postoperative Bone Turnover in Tumor-Induced Osteomalacia.JCEM case reports · 2026Article
- A 65-year-old male with phosphaturic mesenchymal tumor presenting as tumor-induced osteomalacia: a case report.Annals of medicine and surgery (2012) · 2026Article
- Phosphaturic mesenchymal tumor in the temporalis muscle causing tumor-induced osteomalacia: a case report and literature review.Frontiers in medicine · 2026Article
- Adefovir dipivoxil-induced hypophosphatemic osteomalacia and osteoporosis: a case report and literature review.Frontiers in endocrinology · 2026Review
- Serum Phosphorus Is a Fast and Highly Sensitive Marker Predictive of a Complete Cure of Tumor-Induced Osteomalacia.Journal of clinical medicine · 2025Article
- Challenges in Evaluation and Management in Tumor-Induced Osteomalacia: A Retrospective Institutional and Literature-Based Scoping Review in Korean Patients.Journal of bone metabolism · 2025Article
- X-linked hypophosphatemia and tumor-induced osteomalacia: a narrative review and expert opinion on the diagnostic and therapeutic challenges in the era of burosumab.Orphanet journal of rare diseases · 2025Review
- Article
- Postoperative outcome and clinical management of tumor-induced osteomalacia: a single-center retrospective cohort study on 117 patients.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Article
- Biochemical evaluation of X-linked hypophosphatemia and tumor-induced osteomalacia: insights into diagnosis and management.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tumor-induced osteomalacia (TIO), is a rare acquired paraneoplastic syndrome characterized by defective bone mineralization, caused by the overproduction of fibroblast growth factor 23 (FGF23) by a tumor. Material and methods: We conducted a systematic review to identify all case reports of TIO, focusing on those associated with mesenchymal tumors. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) consensus, and we included patients with a diagnosis of TIO and histological confirmation of phosphaturic mesenchymal tumors or resolution of the condition after treatment of the tumor. Bibliographical searches were carried out until December 2023 in the Cochrane Library, Medline and Embase, as well as congress abstracts online. Results: We identified 769 articles with 1979 cases reported. Most patients were adults, with a higher incidence on men. Disease duration before diagnosis is a mean of 4.8 years. Most tumors were histologically classified as PMT. Lower limbs were the predominant location. Hypophosphatemia was present in 99.8 % of patients. The FGF23 was elevated at diagnosis in 95.5 %. Resection of the tumor was the treatment of choice in most of patients. After resection, there was a clinical improvement in 97.6 % of cases, and serum phosphorus and FGF23 levels returned to normal ranges in 91.5 % and 81.4 % of the patients, respectively. Conclusion: TIO is usually misdiagnosed with rheumatological or musculoskeletal disorders. The diagnosis should be suspected in patients with hypophosphatemic osteomalacia, and the measurement of serum FGF23 can be useful for diagnosis and management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.